B+
Bull case
30%
Probability
Target price
$24.50
+15.9% vs current
OSCR
Oscar HealthBNYSE / Insurance
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$19.00
-10.1% vs current
B-
Bear case
25%
Probability
Target price
$14.50
-31.4% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+18.4
Positive
Company
+23.6
Positive
Macro
+18.6
Positive
Pulse
-32.0
Negative
Sentiment proxy
+41.0
Score
AI commentary
Headline tone improved materially after the May 6, 2026 earnings release because results were strong and guidance was reaffirmed. The May 7, 2026 anchor close of $20.87 indicates the market kept a positive post-print reaction, and recent coverage framed the move around the earnings beat and margin improvement. Even so, this remains a medium-conviction setup because the checked packet does not contain a robust verified analyst-revision set, social coverage is not available, and the stock is already above the packet's stale median target summary.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-31catalystQ1 beat and reaffirmed 2026 outlook reset the near-term tape, but durability still needs post-print digestionMedium impact
Oscar reported Q1 2026 total revenue of $4.65 billion, MLR of 70.5%, earnings from operations of $704.1 million, diluted EPS of $2.07, and reaffirmed full-year 2026 guidance on May 6, 2026. Management attributed the margin step-up to higher membership, rate increases, favorable prior-period reserve development, and fixed-cost leverage, which is strong evidence of near-term execution but also means investors still need to test how much of the beat was seasonal versus durable [#8-K-2026-05-06] [#10-Q-2026-05-07].
2026-09-30catalystLucie adds a new growth narrative, but adoption proof is still missingMedium impact
Oscar launched Lucie Health Marketplace in April as a broader consumer shopping and distribution layer, which could support cross-sell and channel expansion, but the checked evidence still lacks disclosed adoption, conversion, or monetization metrics. That keeps Lucie as an option-value catalyst rather than a thesis anchor for now.
2026-12-31catalystThe 2026 profitability recovery thesis remains the main valuation driverHigh impact
The core medium-term question is whether Oscar can convert rapid membership growth into full-year profitability as 2026 progresses. The company reaffirmed its 2026 outlook after Q1, while the February setup had already framed the year around materially better revenue, MLR, SG&A, and operating profit than 2025. If medical cost discipline and risk-adjustment assumptions hold through the higher-cost back half, the recovery case can extend; if they slip, the stock has less room for error after the post-earnings rally [#8-K-2026-05-06] [#10-K-2026-02-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology